TearLab Corporation
 (TEAR)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Wed, Feb. 10, 1:38 PM
    • Thinly traded nano cap TearLab (TEAR +32.9%) rallies on the news that the company has withdrawn its proposed public offering of common stock due to adverse market conditions.
    | Wed, Feb. 10, 1:38 PM
  • Mon, Feb. 1, 12:48 PM
    | Mon, Feb. 1, 12:48 PM
  • Mon, Feb. 1, 12:20 PM
    • On a preliminary  basis, TearLab (TEAR -24.2%) expects its top line for Q4 and full-year 2015 to be $6.8M (+28%) and $25.2M (+28%), respectively.
    • 258 TearLab Osmolarity Systems placed in Q4, 200 under the Flex program, 66 ex-U.S.
    • Final results will be released in March.
    • The company expects to launch its next-generation system in Europe in mid-year and in the U.S. in 2017.
    • It also announces that it intends to divest or wind down its OcuHub, LLC subsidiary.
    | Mon, Feb. 1, 12:20 PM
  • Aug. 3, 2015, 12:46 PM
    | Aug. 3, 2015, 12:46 PM | 8 Comments
  • Apr. 13, 2015, 12:44 PM
    | Apr. 13, 2015, 12:44 PM
  • Jan. 26, 2015, 12:46 PM
    | Jan. 26, 2015, 12:46 PM | 8 Comments
  • Aug. 8, 2014, 3:49 PM
    • First the good news:
    • Tekmira (TKMR +38.1%) on a massive 25M share turnover; Raptor Pharmaceuticals (RPTP +28.2%) on a 4x surge in volume; Clovis Oncology (CLVS +11.6%) on 50% higher volume; RadNet (RDNT +20.4%) on 2x higher volume and Relypsa (RLYP +15%) on 2x higher volume.
    • Now the bad news:
    • TearLab (TEAR -21.2%) on 4x higher volume; Masimo (MASI -10.6%) on 3x higher volume; Volcano (VOLC -19.9%) on a 12x surge in volume and Hanger (HGR -24.9%) on a 16x surge in volume.
    | Aug. 8, 2014, 3:49 PM | 1 Comment
  • Apr. 21, 2014, 12:46 PM
    | Apr. 21, 2014, 12:46 PM | 5 Comments
  • Jan. 29, 2014, 12:46 PM
    | Jan. 29, 2014, 12:46 PM | 1 Comment
  • Aug. 14, 2013, 9:13 AM
    | Aug. 14, 2013, 9:13 AM | 1 Comment
  • Aug. 1, 2013, 12:57 PM
    • Tearlab (TEAR -5.5%) slips on a negative article out of Streetsweeper today.
    • The short seller calls TEAR "a bleeding firm with a long history of failure." adding that many doctors are no longer using its machine for diagnostic eye testing, citing inaccuracies in testing data and calling it an outright lemon.
    | Aug. 1, 2013, 12:57 PM
  • Jul. 25, 2013, 9:39 AM

    TearLab (TEAR +7.8%) soars out of the gate and is now up 25% since Monday. The company priced its public offering at $13.50/ share for gross proceeds of $35.1M. Cramer says the stock is on a roll and although he thinks it may be time to take some profits, he recommends leaving at least half on the table.

    | Jul. 25, 2013, 9:39 AM
  • Jun. 3, 2013, 9:13 AM
    Premarket gainers: ASI +21%. TEAR +11%. PPHM +12%. OSH +9%. CLP +7%. MTL +6%. SODA +5%. INFY +5%.
    Losers: AFFY -27%. INFI -16%. NBG -13%. SNTA -12%.
    | Jun. 3, 2013, 9:13 AM
  • May 14, 2013, 12:45 PM
    Midday top 10 gainers: PDII +31%. UNTK +22%. ALIM +19%. SODA +15%. CHLN +15%. TEAR +14%. ESI +14%. ECTY +14%. BVSN +12%. RVLT 12%.
    Midday top 10 losers: TELOZ -28%. OPXA -19%. SED -16%. STXS -14%. FMAR -13%. VELT -12%. TSRE -12%. TRMD -11%. CCCL -10%. PT -10%.
    | May 14, 2013, 12:45 PM
  • May 14, 2013, 10:23 AM

    TearLab (TEAR +10.6%) ramps higher this morning after reporting Q1 sales that topped the Street's $2.19M estimate. Net revenues soared 486% from the same period last year, and an increase of 54% sequentially from the previous quarter. A total of 388 orders for its TearLab Osmolarity systems were booked in Q1. Net losses for the quarter were $9.1M, including approximately $6.6M in non-cash expense related to the revaluation of warrants issued in June 2011. As of March 31, the company had $12.3M remaining in cash.

    | May 14, 2013, 10:23 AM
  • Aug. 29, 2012, 9:16 AM

    TearLab (TEAR) +6.2% premarket after Canaccord Genuity initiates coverage with a Buy rating a $6 price target, noting the company offers the first point of care instrument that can quantitatively measure and diagnose dry eye disease. The firm says U.S. market potential includes 50,000 eye specialists who see on average six dry eye patients per day, equaling a $1.8B opportunity.

    | Aug. 29, 2012, 9:16 AM
Company Description
TearLab Corp is an in-vitro diagnostic company. The Company commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film.